01.12.2017 | Review | Ausgabe 1/2017 Open Access

Emerging therapies for acute myeloid leukemia
- Zeitschrift:
- Journal of Hematology & Oncology > Ausgabe 1/2017
Background
Drug class/mechanism
|
Agent
|
Suggested patient population
|
Single/combination
|
Phase of development
a
|
Ref.
|
---|---|---|---|---|---|
Cytotoxic chemotherapy
|
|||||
Liposomal formulation of 7 + 3
|
CPX-351
|
≥60 years, sAML, fit for induction therapy
|
Single agent
|
3
|
|
Topoisomerase II inhibitor
|
Vosaroxin
|
≥60 years, R/R
|
With cytarabine
|
3
|
[
19]
|
Epigenetic modifiers
|
|||||
DNMT inhibitor
|
Guadecitabine
|
Unfit for intensive therapy or R/R
|
Single agent
|
3
|
|
IDH1 inhibitor
|
AG-120, IDH305, FT-2102
|
IDH1 mutated
|
Single agent/with AZA or induction and consolidation
|
1b/2
|
|
IDH2 inhibitor
|
Enasidenib (AG-221)
|
IDH2 mutated
|
Single agent/with AZA or induction and consolidation
|
3
|
[
34]
|
HDAC inhibitors
|
Panobinostat
|
Ongoing investigation
|
With HMAs or induction and consolidation
|
1b/2
|
|
Vorinostat
|
3
|
||||
Entinostat
|
2
|
[
45]
|
|||
Pracinostat
|
2
|
[
46]
|
|||
BET inhibitor
|
OTX015
|
Ongoing investigation
|
Single agent
|
1
|
[
47]
|
DOT1L inhibitor
|
Pinometostat
|
MLL-rearranged
|
Single agent
|
1
|
[
49]
|
LSD1 inhibitor
|
Tranylcypromine, GSK2879552, ORY-1001
|
Ongoing investigation
|
Single agent/with ATRA
|
1/2
|
–
|
FLT3 inhibitors
|
Sorafenib
|
FLT3-ITD-mutated R/R
|
With AZA
|
2
|
[
60]
|
Midostaurin
|
FLT3-ITD or
FLT3-TKD, ≤60 years
|
With induction and consolidation
|
3
|
[
63]
|
|
Quizartinib
|
FLT3-ITD-mutated R/R
|
Single agent
|
3
|
||
Crenolanib
|
FLT3-ITD or
FLT3-TKD
|
Single agent/with induction and consolidation
|
2
|
||
Gilteritinib
|
FLT3-ITD or
FLT3-TKD R/R
|
Single agent
|
3
|
[
74]
|
|
Antibody-drug conjugates
|
|||||
Anti-CD33
|
Vadastuximab (SGN-CD33A)
|
CD33+
|
Single agent/with HMAs or induction and consolidation
|
3
|
|
Cell cycle inhibitors
|
|||||
Polo-like kinase inhibitor
|
Volasertib
|
Unfit for intensive therapy
|
With LDAC or decitabine
|
3
|
[
78]
|
Other agents
|
|||||
BCL-2 inhibitor
|
Venetoclax (ABT-199)
|
R/R, or older (≥65 years) and unfit for intensive therapy
|
Single agent/with HMAs or LDAC
|
2
|
|
Aminopeptidase inhibitor
|
Tosedostat
|
≥60 year, R/R or unfit for intensive therapy
|
Single agent/with cytarabine or HMAs
|
2
|